Depressive Disorder, Treatment-Resistant Clinical Trial
Official title:
Treatment-Resistant Depression Cohort in Europe
The purpose of this study is to assess the participants socio-demographics and disease-related characteristics, long-term naturalistic treatment patterns and the clinical, social and economic outcomes of routine clinical practice in the treatment of participants with treatment-resistant depression (TRD) in a variety of European countries.
This TRD cohort study will collect critically important data from routine clinical practice in Europe which will further substantiate the understanding of TRD in European clinical practice, with the aim of improving guidance and informing the development of better treatment strategies for this medically important condition. All data recorded in the case report form (CRF) should be documented in participants' medical records, that will be the primary data source of each participant. Participants who meet the diagnostic criteria for Major Depressive Disorder (MDD) and the diagnostic criteria for TRD, and are initiating or planned to initiate a new antidepressive treatment regimen will participate in the study. The end of the entire study will be 6 months after enrollment of the last participant in the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03851380 -
Improving Brain Stimulation Through Imaging
|
||
| Completed |
NCT04977674 -
Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine
|
Early Phase 1 | |
| Completed |
NCT03207282 -
Treatment Resistant Depression in America Latina
|
||
| Completed |
NCT02691520 -
Epidemiology of Treatment Resistant Depression in Taiwan
|
Phase 4 | |
| Completed |
NCT02452892 -
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
|
N/A | |
| Active, not recruiting |
NCT04159012 -
NESBID: Neuro-Stimulation of the Brain in Depression
|
N/A | |
| Recruiting |
NCT05870501 -
Synaptic Imaging and Network Activity in Treatment Resistant Depression
|
N/A | |
| Completed |
NCT04239651 -
rTMS With and Without iCBT For the Treatment of Resistant Depression (TRD)
|
N/A | |
| Completed |
NCT02493868 -
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
|
Phase 3 | |
| Completed |
NCT04599855 -
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
|
Phase 4 | |
| Completed |
NCT03283670 -
Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies
|
Phase 2 | |
| Recruiting |
NCT03004521 -
Lithium Versus Quetiapine in Treatment Resistant Depression
|
Phase 4 | |
| Recruiting |
NCT04783103 -
Neuromodulation in the Elderly Depressed: a Brain Imaging Pilot Study
|
N/A | |
| Completed |
NCT03434041 -
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
|
Phase 3 | |
| Terminated |
NCT03887624 -
Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.
|
Early Phase 1 | |
| Completed |
NCT02577250 -
Ketamine Infusions for PTSD and Treatment-Resistant Depression
|
Phase 1 | |
| Recruiting |
NCT02610712 -
Clinical Trial of the Use of Ketamine in Treatment Resistant Depression
|
Phase 4 | |
| Completed |
NCT03051256 -
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
|
Phase 2 | |
| Enrolling by invitation |
NCT05581797 -
Psilocybin-assisted Interpersonal Therapy for Depression
|
N/A | |
| Completed |
NCT02782104 -
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
|
Phase 3 |